open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22
Get Citation

First-line treatment of metastatic breast cancer with the use of liposomal doxorubicin (Myocet®) in a female patient with ischaemic heart disease and cardiac dysrhythmia

Jerzy Hanslik

open access

Vol 6, Supp. A (2010)
suplement
Published online: 2010-11-22

Abstract

Anthracyclines are drugs characterised by high efficacy in the treatment of patients with metastatic breast cancer. However, this therapeutic approach is contraindicated in some of the female patients with a history of heart disease in view of the risk of cardiotoxicity. A case report is presented of a female patient with ischaemic heart disease and cardiac dysrhythmia receiving liposomal doxorubicin as part of the first-line treatment of metastatic breast cancer.
Onkol. Prak. Klin. 2010; supl. A: A31–A32

Abstract

Anthracyclines are drugs characterised by high efficacy in the treatment of patients with metastatic breast cancer. However, this therapeutic approach is contraindicated in some of the female patients with a history of heart disease in view of the risk of cardiotoxicity. A case report is presented of a female patient with ischaemic heart disease and cardiac dysrhythmia receiving liposomal doxorubicin as part of the first-line treatment of metastatic breast cancer.
Onkol. Prak. Klin. 2010; supl. A: A31–A32
Get Citation

Keywords

metastatic breast cancer; anthracyclines; cardiotoxicity; liposomal doxorubicin

About this article
Title

First-line treatment of metastatic breast cancer with the use of liposomal doxorubicin (Myocet®) in a female patient with ischaemic heart disease and cardiac dysrhythmia

Journal

Oncology in Clinical Practice

Issue

Vol 6, Supp. A (2010)

Pages

31-32

Published online

2010-11-22

Keywords

metastatic breast cancer
anthracyclines
cardiotoxicity
liposomal doxorubicin

Authors

Jerzy Hanslik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl